Showing 2951-2960 of 4166 results for "".
- Texas Eye and Cataract Clinic Now Accepting Bitcoin for LASIKhttps://modernod.com/news/texas-eye-and-cataract-clinic-now-accepting-bitcoin-for-lasik-surgery/2479096/Texas Eye and Cataract (TEC) announced that it had begun accepting payments for LASIK procedures via the cryptocurrency Bitcoin. Texas Eye and Cataract said it began accepting Bitcoin to help patients looking for innovative ways to finance their LASIK procedures. “We’ve never b
- MAGIC Trial to Assess Factors that Impact Clinical Outcomes of Ab-Interno Canaloplastyhttps://modernod.com/news/magic-trial-to-assess-factors-that-impact-clinical-outcomes-of-ab-interno-canaloplasty/2478993/To assess the various factors that impact the safety and efficacy outcomes of ab-interno canaloplasty, the multicenter “MAGIC” trial has been initiated at eight surgery centers in the United States. A tissue-sparing, implant-free MIGS procedure, ab-interno canaloplasty is akin to cardiac a
- MediPrint Ophthalmics Announces Completion of SIGHT-1 Phase 2a Clinical Studyhttps://modernod.com/news/mediprint-ophthalmics-announces-successful-completion-of-its-sight-1-phase-2a-clinical-study/2478983/MediPrint Ophthalmics announced the successful completion of the first study in its SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatme
- Physicians React: Doctors Worry About Patients Reading Their Clinical Noteshttps://modernod.com/news/physicians-react-doctors-worry-about-patients-reading-their-clinical-notes/2478707/Patients will soon be able to read the notes that physicians make during an episode of care, as well as information about diagnostic testing and imaging results, tests for sexually transmitted diseases, fetal ultrasounds, and cancer biopsies. This open access is raising concerns among physicians,
- Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopiahttps://modernod.com/news/orasis-raises-30-million-to-advance-the-clinical-development-of-novel-treatment-for-presbyopia/2478356/Orasis Pharmaceuticals announced the closing of a $30 million Series C financing. Proceeds from the financing will be used to advance Orasis’ lead eye drop candidate for the treatment of presbyopia sympto
- COVID-19 Clinical and Surgical Protocols: Which Changes Are Here to Stay?https://modernod.com/news/covid-19-clinical-and-surgical-protocols-which-changes-are-here-to-stay/2479512/
- Can Ophthalmic Clinical Trials Proceed During COVID-19 Crisis?https://modernod.com/news/covid-19-can-clinical-trials-proceed/2477676/
- Mayo Clinic’s Jonathan Holmes, MD, Appointed UArizona Chair of Ophthalmologyhttps://modernod.com/news/mayo-clinics-jonathan-holmes-md-appointed-uarizona-chair-of-ophthalmology/2477537/Jonathan M. Holmes, MD, has been appointed chair of the University of Arizona College of Medicine – Tucson Department of Ophthalmology, effective Friday, July 31. Dr. Holmes currently serves as the Joseph E. and Rose Marie Green Professor of Visual Sciences and professor of ophthalmology a
- Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infectionhttps://modernod.com/news/aldeyra-to-screen-clinical-stage-compounds-for-activity-in-covid-19-infection/2477461/Aldeyra Therapeutics announced that it will begin screening its library of novel reactive aldehyde species (RASP) inhibitors, including ADX-629 and reproxalap, for potential anti-inflammatory and antiviral activity in the treatment of COVID-19 infection. ADX-629 and reproxalap are structur
- Aldeyra Announces Strategic Prioritization of Late-Stage Clinical Pipeline in Ocular Diseasehttps://modernod.com/news/aldeyra-announces-strategic-prioritization-of-late-stage-clinical-pipeline-in-ocular-disease/2477378/Aldeyra Therapeutics announced strategic prioritization of late-stage ocular disease programs in allergic conjunctivitis, dry eye disease, and proliferative vitreoretinopathy. In conjunction with the strategic prioritization, Aldeyra appointed ophthalmology drug development expert James A. Gow, M